Veru Inc. (VERU)
USD 0.51
(-2.0%)
USD 0.51
(-2.0%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 7.56 Million USD | -75.27% |
| 2022 | 30.59 Million USD | -36.17% |
| 2021 | 47.92 Million USD | 55.67% |
| 2020 | 30.78 Million USD | 42.16% |
| 2019 | 21.65 Million USD | 146.59% |
| 2018 | 8.78 Million USD | 25.12% |
| 2017 | 7.01 Million USD | -47.42% |
| 2016 | 13.34 Million USD | -29.63% |
| 2015 | 18.96 Million USD | 44.57% |
| 2014 | 13.12 Million USD | -25.04% |
| 2013 | 17.5 Million USD | -15.11% |
| 2012 | 20.62 Million USD | 109.03% |
| 2011 | 9.86 Million USD | -23.67% |
| 2010 | 12.92 Million USD | -4.39% |
| 2009 | 13.51 Million USD | 25.98% |
| 2008 | 10.72 Million USD | 49.93% |
| 2007 | 7.15 Million USD | 30.37% |
| 2006 | 5.48 Million USD | 14.57% |
| 2005 | 4.79 Million USD | 32.28% |
| 2004 | 3.62 Million USD | 0.94% |
| 2003 | 3.58 Million USD | 0.77% |
| 2002 | 3.56 Million USD | 158.37% |
| 2001 | 1.37 Million USD | -36.24% |
| 2000 | 2.16 Million USD | 54.36% |
| 1999 | 1.4 Million USD | 686.68% |
| 1998 | 178.03 Thousand USD | 131.83% |
| 1997 | -559.3 Thousand USD | 65.48% |
| 1996 | -1.62 Million USD | -440.15% |
| 1995 | -300 Thousand USD | -103.45% |
| 1994 | 8.7 Million USD | 55.36% |
| 1993 | 5.6 Million USD | 9.8% |
| 1992 | 5.1 Million USD | -13.56% |
| 1991 | 5.9 Million USD | 28.26% |
| 1990 | 4.6 Million USD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 678.29 Thousand USD | -41.04% |
| 2024 Q3 | 1.33 Million USD | 97.26% |
| 2024 Q1 | 1.15 Million USD | -25.35% |
| 2023 Q2 | 4.09 Million USD | 482.87% |
| 2023 Q3 | 1.23 Million USD | -69.93% |
| 2023 Q1 | 702.05 Thousand USD | 38.91% |
| 2023 FY | 7.56 Million USD | -75.27% |
| 2023 Q4 | 1.54 Million USD | 25.24% |
| 2022 Q4 | 505.4 Thousand USD | -92.85% |
| 2022 Q2 | 11.17 Million USD | -5.63% |
| 2022 Q3 | 7.06 Million USD | -36.75% |
| 2022 FY | 30.59 Million USD | -36.17% |
| 2022 Q1 | 11.84 Million USD | -3.79% |
| 2021 Q4 | 12.3 Million USD | -11.27% |
| 2021 Q3 | 13.87 Million USD | 27.18% |
| 2021 Q1 | 10.83 Million USD | 13.33% |
| 2021 FY | 47.92 Million USD | 55.67% |
| 2021 Q2 | 10.9 Million USD | 0.66% |
| 2020 FY | 30.78 Million USD | 42.16% |
| 2020 Q1 | 7.26 Million USD | 24.63% |
| 2020 Q2 | 7.43 Million USD | 2.3% |
| 2020 Q3 | 6.51 Million USD | -12.34% |
| 2020 Q4 | 9.56 Million USD | 46.68% |
| 2019 Q2 | 4.6 Million USD | -0.76% |
| 2019 Q3 | 6.57 Million USD | 42.58% |
| 2019 Q1 | 4.64 Million USD | 45.53% |
| 2019 FY | 21.65 Million USD | 146.59% |
| 2019 Q4 | 5.83 Million USD | -11.24% |
| 2018 Q2 | 1.19 Million USD | -8.72% |
| 2018 Q4 | 3.19 Million USD | 3.69% |
| 2018 Q1 | 1.31 Million USD | -26.78% |
| 2018 Q3 | 3.07 Million USD | 156.59% |
| 2018 FY | 8.78 Million USD | 25.12% |
| 2017 Q3 | 2.29 Million USD | 79.62% |
| 2017 FY | 7.01 Million USD | -47.42% |
| 2017 Q1 | 1.65 Million USD | -11.57% |
| 2017 Q2 | 1.27 Million USD | -22.67% |
| 2017 Q4 | 1.79 Million USD | -21.8% |
| 2016 Q1 | 5.4 Million USD | 31.01% |
| 2016 Q2 | 2.84 Million USD | -47.33% |
| 2016 Q4 | 1.86 Million USD | -42.21% |
| 2016 Q3 | 3.23 Million USD | 13.63% |
| 2016 FY | 13.34 Million USD | -29.63% |
| 2015 Q4 | 4.12 Million USD | -10.99% |
| 2015 Q1 | 3.81 Million USD | 32.32% |
| 2015 Q2 | 6.39 Million USD | 67.4% |
| 2015 FY | 18.96 Million USD | 44.57% |
| 2015 Q3 | 4.63 Million USD | -27.55% |
| 2014 Q3 | 4.17 Million USD | 74.79% |
| 2014 Q1 | 3.67 Million USD | 61.69% |
| 2014 Q4 | 2.88 Million USD | -30.78% |
| 2014 FY | 13.12 Million USD | -25.04% |
| 2014 Q2 | 2.38 Million USD | -35.14% |
| 2013 Q2 | 5.52 Million USD | -7.48% |
| 2013 Q4 | 2.27 Million USD | -39.22% |
| 2013 FY | 17.5 Million USD | -15.11% |
| 2013 Q3 | 3.74 Million USD | -32.19% |
| 2013 Q1 | 5.96 Million USD | 3.76% |
| 2012 Q1 | 5.01 Million USD | 18.66% |
| 2012 Q2 | 4.56 Million USD | -9.07% |
| 2012 FY | 20.62 Million USD | 109.03% |
| 2012 Q4 | 5.75 Million USD | 8.62% |
| 2012 Q3 | 5.29 Million USD | 16.07% |
| 2011 Q1 | 2.01 Million USD | -56.18% |
| 2011 FY | 9.86 Million USD | -23.67% |
| 2011 Q4 | 4.22 Million USD | 133.08% |
| 2011 Q2 | 1.8 Million USD | -10.4% |
| 2011 Q3 | 1.81 Million USD | 0.36% |
| 2010 Q2 | 4.18 Million USD | 30.51% |
| 2010 FY | 12.92 Million USD | -4.39% |
| 2010 Q3 | 939.44 Thousand USD | -77.53% |
| 2010 Q1 | 3.2 Million USD | -16.51% |
| 2010 Q4 | 4.6 Million USD | 389.91% |
| 2009 FY | 13.51 Million USD | 25.98% |
| 2009 Q2 | 3.89 Million USD | 59.47% |
| 2009 Q3 | 3.34 Million USD | -14.01% |
| 2009 Q4 | 3.83 Million USD | 14.59% |
| 2009 Q1 | 2.44 Million USD | -30.52% |
| 2008 Q4 | 3.51 Million USD | 61.33% |
| 2008 Q3 | 2.17 Million USD | -18.52% |
| 2008 Q2 | 2.67 Million USD | 12.96% |
| 2008 Q1 | 2.36 Million USD | 16.5% |
| 2008 FY | 10.72 Million USD | 49.93% |
| 2007 Q3 | 1.81 Million USD | -10.89% |
| 2007 Q1 | 1.27 Million USD | -15.56% |
| 2007 Q4 | 2.03 Million USD | 12.03% |
| 2007 Q2 | 2.03 Million USD | 59.14% |
| 2007 FY | 7.15 Million USD | 30.37% |
| 2006 Q4 | 1.51 Million USD | 26.76% |
| 2006 Q3 | 1.19 Million USD | -21.93% |
| 2006 Q2 | 1.52 Million USD | -5.17% |
| 2006 Q1 | 1.61 Million USD | 14.09% |
| 2006 FY | 5.48 Million USD | 14.57% |
| 2005 FY | 4.79 Million USD | 32.28% |
| 2005 Q2 | 1.56 Million USD | 195.84% |
| 2005 Q4 | 1.41 Million USD | 10.23% |
| 2005 Q3 | 1.28 Million USD | -18.06% |
| 2005 Q1 | 529.15 Thousand USD | -14.52% |
| 2004 Q2 | 796.79 Thousand USD | -8.86% |
| 2004 Q4 | 619.06 Thousand USD | -53.53% |
| 2004 Q3 | 1.33 Million USD | 67.2% |
| 2004 FY | 3.62 Million USD | 0.94% |
| 2004 Q1 | 874.23 Thousand USD | -12.32% |
| 2003 Q1 | 978.64 Thousand USD | -5.01% |
| 2003 Q2 | 594.03 Thousand USD | -39.3% |
| 2003 Q3 | 1.01 Million USD | 71.52% |
| 2003 FY | 3.58 Million USD | 0.77% |
| 2003 Q4 | 997.12 Thousand USD | -2.14% |
| 2002 Q4 | 1.03 Million USD | 12.31% |
| 2002 Q3 | 917.35 Thousand USD | 26.87% |
| 2002 Q1 | 298.76 Thousand USD | -28.49% |
| 2002 FY | 3.56 Million USD | 158.37% |
| 2002 Q2 | 723.09 Thousand USD | 142.03% |
| 2001 Q3 | 658.54 Thousand USD | 55.71% |
| 2001 Q2 | 422.91 Thousand USD | 46.63% |
| 2001 Q1 | 288.43 Thousand USD | -62.87% |
| 2001 FY | 1.37 Million USD | -36.24% |
| 2001 Q4 | 417.81 Thousand USD | -36.56% |
| 2000 FY | 2.16 Million USD | 54.36% |
| 2000 Q4 | 776.9 Thousand USD | 98.16% |
| 2000 Q3 | 392.06 Thousand USD | -42.3% |
| 2000 Q2 | 679.45 Thousand USD | 28.66% |
| 2000 Q1 | 528.09 Thousand USD | 5.62% |
| 1999 Q3 | 20 Thousand USD | 108.0% |
| 1999 Q4 | 500 Thousand USD | 2400.0% |
| 1999 Q2 | -250 Thousand USD | 0.0% |
| 1999 Q1 | - USD | 100.0% |
| 1999 FY | 1.4 Million USD | 686.68% |
| 1998 FY | 178.03 Thousand USD | 131.83% |
| 1998 Q4 | -121.97 Thousand USD | -140.66% |
| 1998 Q3 | 300 Thousand USD | 0.0% |
| 1998 Q1 | -200 Thousand USD | 22.87% |
| 1998 Q2 | 300 Thousand USD | 250.0% |
| 1997 Q4 | -259.3 Thousand USD | -229.65% |
| 1997 Q3 | 200 Thousand USD | 150.0% |
| 1997 Q2 | -400 Thousand USD | -100.0% |
| 1997 Q1 | -200 Thousand USD | 85.92% |
| 1997 FY | -559.3 Thousand USD | 65.48% |
| 1996 Q4 | -1.42 Million USD | 0.0% |
| 1996 Q3 | - USD | 100.0% |
| 1996 FY | -1.62 Million USD | -440.15% |
| 1996 Q2 | -200 Thousand USD | -200.0% |
| 1996 Q1 | 200 Thousand USD | 125.0% |
| 1995 FY | -300 Thousand USD | -103.45% |
| 1995 Q4 | -800 Thousand USD | -500.0% |
| 1995 Q3 | 200 Thousand USD | 100.0% |
| 1995 Q2 | 100 Thousand USD | -90.0% |
| 1995 Q1 | 1 Million USD | -37.5% |
| 1994 Q1 | 3.1 Million USD | 181.82% |
| 1994 Q2 | 1.8 Million USD | -41.94% |
| 1994 Q3 | 2.3 Million USD | 27.78% |
| 1994 Q4 | 1.6 Million USD | -30.43% |
| 1994 FY | 8.7 Million USD | 55.36% |
| 1993 Q2 | 1.7 Million USD | 112.5% |
| 1993 Q3 | 1.9 Million USD | 11.76% |
| 1993 Q4 | 1.1 Million USD | -42.11% |
| 1993 FY | 5.6 Million USD | 9.8% |
| 1993 Q1 | 800 Thousand USD | -11.11% |
| 1992 Q1 | 600 Thousand USD | -40.0% |
| 1992 Q4 | 900 Thousand USD | -47.06% |
| 1992 Q3 | 1.7 Million USD | -10.53% |
| 1992 Q2 | 1.9 Million USD | 216.67% |
| 1992 FY | 5.1 Million USD | -13.56% |
| 1991 Q4 | 1 Million USD | -62.96% |
| 1991 Q3 | 2.7 Million USD | 80.0% |
| 1991 Q1 | 700 Thousand USD | 0.0% |
| 1991 Q2 | 1.5 Million USD | 114.29% |
| 1991 FY | 5.9 Million USD | 28.26% |
| 1990 Q1 | 1.3 Million USD | 0.0% |
| 1990 FY | 4.6 Million USD | 0.0% |
| 1990 Q3 | 8.9 Million USD | 535.71% |
| 1990 Q2 | 1.4 Million USD | 7.69% |
| 1989 Q3 | 1.3 Million USD | 0.0% |
| 1989 Q4 | 1.3 Million USD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Sangamo Therapeutics, Inc. | -45.32 Million USD | 116.693% |
| IDEAYA Biosciences, Inc. | -106.12 Million USD | 107.129% |
| Eton Pharmaceuticals, Inc. | 21.06 Million USD | 64.076% |
| Autolus Therapeutics plc | -4.86 Million USD | 255.454% |
| Greenwich LifeSciences, Inc. | -3612.00 USD | 209566.445% |
| Enlivex Therapeutics Ltd. | -835 Thousand USD | 1006.099% |
| Shattuck Labs, Inc. | -2.38 Million USD | 417.23% |
| LENZ Therapeutics, Inc. | -2.4 Million USD | 414.33% |
| CervoMed Inc. | -1.29 Million USD | 684.862% |
| Rocket Pharmaceuticals, Inc. | -7.09 Million USD | 206.592% |
| Corbus Pharmaceuticals Holdings, Inc. | -31.16 Million USD | 124.275% |
| Aptose Biosciences Inc. | -474.54 Thousand USD | 1694.354% |
| Precision BioSciences, Inc. | 40.47 Million USD | 81.306% |
| Dyadic International, Inc. | 922.95 Thousand USD | -719.749% |
| TScan Therapeutics, Inc. | -67.1 Million USD | 111.275% |
| Intensity Therapeutics, Inc. | -147 Thousand USD | 5246.89% |
| Nektar Therapeutics | 53.47 Million USD | 85.852% |
| CytomX Therapeutics, Inc. | 99.03 Million USD | 92.361% |
| VYNE Therapeutics Inc. | 424 Thousand USD | -1684.417% |
| EyePoint Pharmaceuticals, Inc. | 41.38 Million USD | 81.719% |
| Leap Therapeutics, Inc. | -427 Thousand USD | 1871.88% |
| Adaptive Biotechnologies Corporation | 94.72 Million USD | 92.013% |
| GRI Bio, Inc. | 10.84 Million USD | 30.21% |
| Xenetic Biosciences, Inc. | 2.53 Million USD | -197.873% |
| Tenaya Therapeutics, Inc. | -8.68 Million USD | 187.095% |
| NeuroSense Therapeutics Ltd. | -97 Thousand USD | 7899.926% |
| Psyence Biomedical Ltd. | -240.00 USD | 3152570.0% |
| IGM Biosciences, Inc. | -211.66 Million USD | 103.575% |
| INmune Bio, Inc. | 155 Thousand USD | -4781.244% |
| Opthea Limited | 21.72 Thousand USD | -34733.923% |
| Milestone Pharmaceuticals Inc. | 402 Thousand USD | -1782.072% |
| Omega Therapeutics, Inc. | -62.77 Million USD | 112.052% |
| Verastem, Inc. | -62 Thousand USD | 12303.11% |
| Abeona Therapeutics Inc. | 2.43 Million USD | -210.716% |
| Pliant Therapeutics, Inc. | -261 Thousand USD | 2998.823% |
| Tonix Pharmaceuticals Holding Corp. | 3.02 Million USD | -149.948% |
| Ligand Pharmaceuticals Incorporated | 119.75 Million USD | 93.682% |
| NextCure, Inc. | -3.68 Million USD | 305.373% |
| Inhibikase Therapeutics, Inc. | -13.35 Million USD | 156.64% |
| Organovo Holdings, Inc. | -5.38 Million USD | 240.396% |
| Lixte Biotechnology Holdings, Inc. | - USD | -Infinity% |
| Arvinas, Inc. | 71.8 Million USD | 89.462% |
| Ovid Therapeutics Inc. | -1.2 Million USD | 727.94% |
| CASI Pharmaceuticals, Inc. | 20.05 Million USD | 62.268% |
| Rani Therapeutics Holdings, Inc. | -822 Thousand USD | 1020.429% |
| Centessa Pharmaceuticals plc | 6.06 Million USD | -24.718% |
| Arcturus Therapeutics Holdings Inc. | 154.79 Million USD | 95.112% |
| Syros Pharmaceuticals, Inc. | -98.21 Million USD | 107.703% |
| Senti Biosciences, Inc. | -2.68 Million USD | 381.995% |
| BioRestorative Therapies, Inc. | 145.8 Thousand USD | -5089.251% |
| Apollomics, Inc. | 127 Thousand USD | -5857.424% |
| PureTech Health plc | -1.6 Million USD | 571.986% |
| Oncternal Therapeutics, Inc. | -28.96 Million USD | 126.118% |
| Barinthus Biotherapeutics plc | 802 Thousand USD | -843.383% |
| Kymera Therapeutics, Inc. | -110.48 Million USD | 106.848% |
| Synaptogenix, Inc. | -6347.00 USD | 119304.79% |
| ChromaDex Corporation | 50.78 Million USD | 85.101% |
| Beam Therapeutics Inc. | -59.67 Million USD | 112.679% |
| Monopar Therapeutics Inc. | - USD | -Infinity% |
| Akebia Therapeutics, Inc. | 120.47 Million USD | 93.72% |
| Nurix Therapeutics, Inc. | -112.16 Million USD | 106.746% |
| Apellis Pharmaceuticals, Inc. | 338.08 Million USD | 97.762% |
| Dermata Therapeutics, Inc. | - USD | -Infinity% |
| Gritstone bio, Inc. | -6.26 Million USD | 220.861% |
| Mesoblast Limited | -9.81 Million USD | 177.085% |
| Virpax Pharmaceuticals, Inc. | - USD | -Infinity% |
| Xeris Biopharma Holdings, Inc. | 135.26 Million USD | 94.407% |
| Fate Therapeutics, Inc. | -98.16 Million USD | 107.708% |
| MediWound Ltd. | 3.57 Million USD | -111.457% |
| BioXcel Therapeutics, Inc. | 120 Thousand USD | -6204.94% |
| Fortress Biotech, Inc. | 57.85 Million USD | 86.922% |
| Fractyl Health, Inc. Common Stock | 43 Thousand USD | -17495.181% |
| Achilles Therapeutics plc | -4.73 Million USD | 259.913% |
| Seres Therapeutics, Inc. | 125.62 Million USD | 93.977% |
| Checkpoint Therapeutics, Inc. | -43.46 Million USD | 117.408% |
| Atossa Therapeutics, Inc. | -23 Thousand USD | 32995.339% |
| Zai Lab Limited | 170.9 Million USD | 95.573% |
| Fresh Tracks Therapeutics, Inc. | 8 Million USD | 5.497% |
| Lyell Immunopharma, Inc. | 130 Thousand USD | -5719.945% |
| Vanda Pharmaceuticals Inc. | 177.84 Million USD | 95.746% |
| Tarsus Pharmaceuticals, Inc. | 15.85 Million USD | 52.277% |
| InMed Pharmaceuticals Inc. | -6.98 Billion USD | 100.108% |
| FibroGen, Inc. | 128.9 Million USD | 94.131% |
| Celcuity Inc. | -142.77 Thousand USD | 5399.308% |
| SeaStar Medical Holding Corporation | - USD | -Infinity% |
| ContextLogic Inc. | 59 Million USD | 87.176% |
| GH Research PLC | -315 Thousand USD | 2501.882% |
| HOOKIPA Pharma Inc. | 16.57 Million USD | 54.359% |
| Cyclacel Pharmaceuticals, Inc. | 389 Thousand USD | -1844.969% |
| ImmuCell Corporation | 4.39 Million USD | -72.098% |
| Amylyx Pharmaceuticals, Inc. | 355.34 Million USD | 97.871% |
| Amarin Corporation plc | 165.54 Million USD | 95.43% |
| TG Therapeutics, Inc. | 219.1 Million USD | 96.547% |
| Aptevo Therapeutics Inc. | -567 Thousand USD | 1434.379% |
| Jasper Therapeutics, Inc. | -1.1 Million USD | 782.845% |
| Foghorn Therapeutics Inc. | -75.53 Million USD | 110.017% |
| Y-mAbs Therapeutics, Inc. | 73.4 Million USD | 89.693% |
| Aptorum Group Limited | -1.11 Million USD | 778.748% |
| Ultragenyx Pharmaceutical Inc. | 389.04 Million USD | 98.055% |
| BioCryst Pharmaceuticals, Inc. | 326.75 Million USD | 97.684% |
| Chemomab Therapeutics Ltd. | -66.82 Thousand USD | 11421.663% |
| Arrowhead Pharmaceuticals, Inc. | 240.73 Million USD | 96.857% |
| TransCode Therapeutics, Inc. | -516.74 Thousand USD | 1564.148% |
| RAPT Therapeutics, Inc. | -3.55 Million USD | 313.065% |
| Ardelyx, Inc. | 106.66 Million USD | 92.907% |
| Ainos, Inc. | -253.73 Thousand USD | 3081.846% |
| Lyra Therapeutics, Inc. | -46.47 Million USD | 116.281% |
| Prothena Corporation plc | -129.2 Million USD | 105.856% |
| HilleVax, Inc. | -2.15 Million USD | 450.924% |
| Adaptimmune Therapeutics plc | 50.42 Million USD | 84.995% |
| Celularity Inc. | 6.75 Million USD | -12.005% |
| Rallybio Corporation | -150 Thousand USD | 5143.952% |
| Cue Biopharma, Inc. | -32.6 Million USD | 123.203% |
| Omeros Corporation | -69.77 Million USD | 110.843% |
| Humacyte, Inc. | -76.55 Million USD | 109.884% |
| Immunocore Holdings plc | 248.39 Million USD | 96.954% |
| Cocrystal Pharma, Inc. | -15.16 Million USD | 149.878% |
| Blueprint Medicines Corporation | 236.58 Million USD | 96.802% |
| IO Biotech, Inc. | -756 Thousand USD | 1100.784% |
| MEI Pharma, Inc. | 49.32 Million USD | 84.662% |
| GT Biopharma, Inc. | - USD | -Infinity% |
| Cabaletta Bio, Inc. | -1.42 Million USD | 630.57% |
| Summit Therapeutics Inc. | -2.05 Million USD | 469.07% |
| Alaunos Therapeutics, Inc. | -4.79 Million USD | 257.689% |
| Marinus Pharmaceuticals, Inc. | 29.05 Million USD | 73.96% |
| Scholar Rock Holding Corporation | -2.84 Million USD | 366.031% |
| Pulmatrix, Inc. | -8.22 Million USD | 192.043% |
| Elicio Therapeutics, Inc. | -1.17 Million USD | 746.661% |
| X4 Pharmaceuticals, Inc. | -1.99 Million USD | 479.055% |
| Vigil Neuroscience, Inc. | -399 Thousand USD | 1996.223% |
| Acelyrin, Inc. | -115 Thousand USD | 6679.068% |
| Intellia Therapeutics, Inc. | -398.79 Million USD | 101.897% |
| Cytokinetics, Incorporated | -322.59 Million USD | 102.345% |
| Vor Biopharma Inc. | -3.49 Million USD | 316.665% |
| Evogene Ltd. | 1.39 Million USD | -440.81% |
| Replimune Group, Inc. | -2.65 Million USD | 384.969% |
| Applied Therapeutics, Inc. | -43.91 Million USD | 117.23% |
| PDS Biotechnology Corporation | -57.32 Thousand USD | 13298.074% |
| Hoth Therapeutics, Inc. | - USD | -Infinity% |
| BridgeBio Pharma, Inc. | 6.85 Million USD | -10.339% |
| AEON Biopharma, Inc. | - USD | -Infinity% |
| BioLineRx Ltd. | 1.1 Million USD | -582.845% |
| Galectin Therapeutics Inc. | -33 Thousand USD | 23027.055% |
| Atai Life Sciences N.V. | -5000.00 USD | 151418.56% |
| Aerovate Therapeutics, Inc. | -96 Thousand USD | 7981.175% |
| VistaGen Therapeutics, Inc. | 496 Thousand USD | -1425.389% |
| Zentalis Pharmaceuticals, Inc. | -1.38 Million USD | 644.703% |
| Sagimet Biosciences Inc. | 2 Million USD | -278.296% |
| MediciNova, Inc. | 979.7 Thousand USD | -672.266% |
| Praxis Precision Medicines, Inc. | -84.31 Million USD | 108.973% |
| MiMedx Group, Inc. | 266.84 Million USD | 97.165% |
| Cardio Diagnostics Holdings, Inc. | -94.55 Thousand USD | 8101.616% |
| Axsome Therapeutics, Inc. | 244.53 Million USD | 96.906% |
| PTC Therapeutics, Inc. | 872.33 Million USD | 99.133% |
| Mereo BioPharma Group plc | 7.42 Million USD | -1.884% |
| Syndax Pharmaceuticals, Inc. | -12 Thousand USD | 63149.4% |
| NRx Pharmaceuticals, Inc. | -5000.00 USD | 151418.56% |
| Dyne Therapeutics, Inc. | -2.46 Million USD | 407.433% |
| BriaCell Therapeutics Corp. | - USD | -Infinity% |
| Allakos Inc. | -6.14 Million USD | 223.204% |
| scPharmaceuticals Inc. | 9.78 Million USD | 22.655% |
| Fulcrum Therapeutics, Inc. | -68.99 Million USD | 110.966% |
| Corcept Therapeutics Incorporated | 475.89 Million USD | 98.41% |
| NLS Pharmaceutics AG | -11.4 Thousand USD | 66421.248% |
| Precigen, Inc. | 106 Thousand USD | -7037.668% |
| XOMA Corporation | 3.86 Million USD | -95.958% |
| Kezar Life Sciences, Inc. | -70.08 Million USD | 110.795% |
| Incyte Corporation | 3.44 Billion USD | 99.78% |
| Alzamend Neuro, Inc. | -50.74 Thousand USD | 15011.171% |
| Cara Therapeutics, Inc. | 14.79 Million USD | 48.858% |
| Aligos Therapeutics, Inc. | 12.46 Million USD | 39.278% |
| Seer, Inc. | 7.02 Million USD | -7.669% |
| Reviva Pharmaceuticals Holdings, Inc. | - USD | -Infinity% |
| CRISPR Therapeutics AG | 240.95 Million USD | 96.86% |
| Akero Therapeutics, Inc. | -29 Thousand USD | 26189.407% |
| Eliem Therapeutics, Inc. | - USD | -Infinity% |
| EyeGate Pharmaceuticals, Inc. | 13.00 USD | -58199346.154% |
| Akari Therapeutics, Plc | -4000.00 USD | 189248.2% |
| Novavax, Inc. | 639.93 Million USD | 98.818% |
| Lexaria Bioscience Corp. | 194.7 Thousand USD | -3785.782% |
| UroGen Pharma Ltd. | 73.35 Million USD | 89.685% |
| Sutro Biopharma, Inc. | -26.69 Million USD | 128.343% |
| Entera Bio Ltd. | -56 Thousand USD | 13610.586% |
| Lisata Therapeutics, Inc. | -189 Thousand USD | 4103.137% |
| Stoke Therapeutics, Inc. | 4.05 Million USD | -86.767% |
| Chimerix, Inc. | 324 Thousand USD | -2235.163% |
| Reneo Pharmaceuticals, Inc. | -525 Thousand USD | 1541.129% |
| Phathom Pharmaceuticals, Inc. | 515 Thousand USD | -1369.112% |
| Outlook Therapeutics, Inc. | -44.18 Thousand USD | 17222.133% |
| Jazz Pharmaceuticals plc | 3.39 Billion USD | 99.777% |
| AnaptysBio, Inc. | 14.78 Million USD | 48.813% |
| Aprea Therapeutics, Inc. | 576.17 Thousand USD | -1213.121% |
| Portage Biotech Inc. | -54 Thousand USD | 14110.978% |
| Olema Pharmaceuticals, Inc. | -377 Thousand USD | 2106.877% |
| PMV Pharmaceuticals, Inc. | -1.25 Million USD | 701.904% |
| OKYO Pharma Limited | -7506.16 USD | 100896.253% |
| Qualigen Therapeutics, Inc. | -4495.00 USD | 168418.754% |
| Cadrenal Therapeutics, Inc. Common Stock | -1980.00 USD | 382217.576% |
| Processa Pharmaceuticals, Inc. | -222.00 USD | 3408175.676% |
| AbCellera Biologics Inc. | 38.02 Million USD | 80.103% |
| Genprex, Inc. | -15 Thousand USD | 50526.073% |
| Neumora Therapeutics, Inc. Common Stock | -668 Thousand USD | 1232.624% |
| NLS Pharmaceutics AG | -11.4 Thousand USD | 66421.248% |
| Virios Therapeutics, Inc. | - USD | -Infinity% |
| Daré Bioscience, Inc. | 2.76 Million USD | -173.185% |
| Titan Pharmaceuticals, Inc. | -1.72 Million USD | 537.59% |
| Bicycle Therapeutics plc | -129.52 Million USD | 105.842% |
| Revolution Medicines, Inc. Warrant | -399.66 Million USD | 101.893% |
| Protagonist Therapeutics, Inc. | 56.68 Million USD | 86.653% |
| Erasca, Inc. | -3.73 Million USD | 302.731% |
| bluebird bio, Inc. | -4.03 Million USD | 287.74% |
| Pieris Pharmaceuticals, Inc. | 1 Million USD | -649.844% |
| BioMarin Pharmaceutical Inc. | 1.9 Billion USD | 99.603% |
| DBV Technologies S.A. | 15.72 Million USD | 51.895% |
| Fortress Biotech, Inc. | 57.85 Million USD | 86.922% |
| Avidity Biosciences, Inc. | -181.4 Million USD | 104.171% |
| CorMedix Inc. | -205.56 Thousand USD | 3780.606% |
| Travere Therapeutics, Inc. | 133.78 Million USD | 94.345% |
| Sensei Biotherapeutics, Inc. | -571 Thousand USD | 1425.031% |
| Orchestra BioMed Holdings, Inc. | 2.57 Million USD | -193.937% |
| Spruce Biosciences, Inc. | -39.34 Million USD | 119.231% |
| Celldex Therapeutics, Inc. | -111.12 Million USD | 106.808% |
| Cartesian Therapeutics, Inc. | 24.45 Million USD | 69.057% |
| Cogent Biosciences, Inc. | -3.58 Million USD | 310.868% |
| Onconetix, Inc. | -1.12 Million USD | 771.235% |
| Ocuphire Pharma, Inc. | 19.04 Million USD | 60.269% |
| Prime Medicine, Inc. | -147.9 Million USD | 105.115% |
| Adagene Inc. | 18.11 Million USD | 58.226% |
| Inhibrx Biosciences, Inc. | 609 Thousand USD | -1142.353% |
| GlycoMimetics, Inc. | -143.3 Thousand USD | 5379.745% |
| Maravai LifeSciences Holdings, Inc. | 140.2 Million USD | 94.604% |
| Verve Therapeutics, Inc. | -173.18 Million USD | 104.369% |
| Voyager Therapeutics, Inc. | 157.83 Million USD | 95.206% |
| SciSparc Ltd. | 2.19 Million USD | -244.532% |
| Revelation Biosciences, Inc. | -25.04 Thousand USD | 30304.511% |
| Minerva Neurosciences, Inc. | -30.98 Thousand USD | 24520.399% |
| Astria Therapeutics, Inc. | - USD | -Infinity% |
| Spero Therapeutics, Inc. | 96.36 Million USD | 92.149% |
| Tevogen Bio Holdings Inc. | - USD | -Infinity% |
| Arcutis Biotherapeutics, Inc. | 54.61 Million USD | 86.148% |
| Marker Therapeutics, Inc. | -7.1 Million USD | 206.478% |
| Alnylam Pharmaceuticals, Inc. | 1.51 Billion USD | 99.502% |
| Artelo Biosciences, Inc. | - USD | -Infinity% |
| 2seventy bio, Inc. | 98.28 Million USD | 92.302% |
| ADMA Biologics, Inc. | 88.21 Million USD | 91.424% |
| Clene Inc. | 533 Thousand USD | -1319.499% |
| Capricor Therapeutics, Inc. | 24.1 Million USD | 68.618% |
| Boundless Bio, Inc. Common Stock | -957 Thousand USD | 890.588% |
| Recursion Pharmaceuticals, Inc. | 1.98 Million USD | -280.58% |
| Citius Pharmaceuticals, Inc. | -194.31 Thousand USD | 3993.621% |
| Contineum Therapeutics, Inc. Class A Common Stock | 49.8 Million USD | 84.809% |
| Absci Corporation | -41.84 Million USD | 118.079% |
| Regeneron Pharmaceuticals, Inc. | 11.3 Billion USD | 99.933% |
| Surrozen, Inc. | -27.23 Million USD | 127.785% |
| Caribou Biosciences, Inc. | -77.59 Million USD | 109.75% |
| Janux Therapeutics, Inc. | -46.83 Million USD | 116.153% |
| Cingulate Inc. | -582.91 Thousand USD | 1397.94% |
| Galmed Pharmaceuticals Ltd. | -31 Thousand USD | 24506.219% |
| Tenax Therapeutics, Inc. | -7570.00 USD | 100046.209% |
| Jaguar Health, Inc. | 7.72 Million USD | 2.047% |
| Terns Pharmaceuticals, Inc. | -881 Thousand USD | 958.789% |
| ACADIA Pharmaceuticals Inc. | 680.7 Million USD | 98.889% |
| Kronos Bio, Inc. | 1.37 Million USD | -451.452% |
| Innoviva, Inc. | 261.06 Million USD | 97.102% |
| Bolt Biotherapeutics, Inc. | -53.66 Million USD | 114.098% |
| Entrada Therapeutics, Inc. | 29.12 Million USD | 74.026% |
| ZyVersa Therapeutics, Inc. | -10.4 Thousand USD | 72849.308% |
| Soligenix, Inc. | 97.31 Thousand USD | -7674.998% |
| AlloVir, Inc. | -398 Thousand USD | 2000.987% |
| Century Therapeutics, Inc. | -10.8 Million USD | 169.997% |
| ORIC Pharmaceuticals, Inc. | -1.03 Million USD | 833.133% |
| Kura Oncology, Inc. | -849 Thousand USD | 991.158% |
| Ocean Biomedical, Inc. | - USD | -Infinity% |
| Mineralys Therapeutics, Inc. | - USD | -Infinity% |
| Eterna Therapeutics Inc. | -168 Thousand USD | 4603.529% |
| SELLAS Life Sciences Group, Inc. | - USD | -Infinity% |
| Heron Therapeutics, Inc. | 61.93 Million USD | 87.785% |
| SAB Biotherapeutics, Inc. | -1.5 Million USD | 602.289% |
| Pasithea Therapeutics Corp. | -648.45 Thousand USD | 1266.764% |
| Entero Therapeutics, Inc. | -29.27 Thousand USD | 25945.214% |
| HCW Biologics Inc. | -574.82 Thousand USD | 1416.216% |
| C4 Therapeutics, Inc. | -96.95 Million USD | 107.804% |
| Atara Biotherapeutics, Inc. | -313 Thousand USD | 2517.229% |
| Coherus BioSciences, Inc. | 94.46 Million USD | 91.99% |
| Lantern Pharma Inc. | -174.84 Thousand USD | 4427.27% |
| Histogen Inc. | 3.76 Million USD | -100.741% |
| Surrozen, Inc. | -27.23 Million USD | 127.785% |
| Eledon Pharmaceuticals, Inc. | -374 Thousand USD | 2122.975% |
| Kodiak Sciences Inc. | -25.94 Million USD | 129.159% |
| MoonLake Immunotherapeutics | -13.15 Thousand USD | 57600.593% |
| Hepion Pharmaceuticals, Inc. | -67.13 Thousand USD | 11370.394% |
| Adverum Biotechnologies, Inc. | -2.04 Million USD | 470.153% |
| Avalo Therapeutics, Inc. | 640 Thousand USD | -1082.176% |
| Moderna, Inc. | 2.15 Billion USD | 99.649% |
| Ionis Pharmaceuticals, Inc. | 778.51 Million USD | 99.028% |
| Turnstone Biologics Corp. | 16.5 Million USD | 54.163% |
| Immix Biopharma, Inc. | -5468.00 USD | 138467.374% |
| Tiziana Life Sciences Ltd | -51 Thousand USD | 14935.153% |
| Aurinia Pharmaceuticals Inc. | 161.36 Million USD | 95.311% |
| Exelixis, Inc. | 1.75 Billion USD | 99.57% |
| Monte Rosa Therapeutics, Inc. | -6.22 Million USD | 221.6% |
| Wave Life Sciences Ltd. | 104.09 Million USD | 92.732% |
| Conduit Pharmaceuticals Inc. | - USD | -Infinity% |
| Alkermes plc | 1.37 Billion USD | 99.45% |
| Jasper Therapeutics, Inc. | -1.1 Million USD | 782.845% |
| Arcellx, Inc. | 108.27 Million USD | 93.013% |
| ESSA Pharma Inc. | -118.49 Thousand USD | 6485.234% |
| TNF Pharmaceuticals, Inc. | - USD | -Infinity% |
| Avid Bioservices, Inc. | 7.31 Million USD | -3.388% |
| Insmed Incorporated | 239.63 Million USD | 96.843% |
| Cardiff Oncology, Inc. | -32.36 Million USD | 123.374% |
| Enanta Pharmaceuticals, Inc. | 79.2 Million USD | 90.448% |
| Moolec Science SA | -143.3 Thousand USD | 5379.598% |
| RenovoRx, Inc. | - USD | -Infinity% |
| Acumen Pharmaceuticals, Inc. | -42.31 Million USD | 117.879% |
| Geron Corporation | -123.5 Million USD | 106.126% |
| LAVA Therapeutics N.V. | 3.28 Million USD | -130.177% |
| Verrica Pharmaceuticals Inc. | 4.37 Million USD | -72.817% |
| Royalty Pharma plc | 1.79 Billion USD | 99.578% |
| OmniAb, Inc. | 14.66 Million USD | 48.415% |
| Alector, Inc. | -95.05 Million USD | 107.96% |
| Atea Pharmaceuticals, Inc. | -70.09 Million USD | 110.795% |
| Mersana Therapeutics, Inc. | -111.41 Million USD | 106.791% |
| Humacyte, Inc. | -76.55 Million USD | 109.884% |
| Structure Therapeutics Inc. | -949.17 Thousand USD | 897.107% |
| Revance Therapeutics, Inc. | 81.87 Million USD | 90.759% |
| 89bio, Inc. | -273 Thousand USD | 2871.402% |
| Avenue Therapeutics, Inc. | - USD | -Infinity% |
| Aura Biosciences, Inc. | -1.29 Million USD | 684.242% |
| Immunic, Inc. | -111 Thousand USD | 6916.151% |
| Veracyte, Inc. | 248.14 Million USD | 96.951% |
| Genelux Corporation | -848 Thousand USD | 992.208% |
| Trevi Therapeutics, Inc. | -123 Thousand USD | 6251.161% |
| Adial Pharmaceuticals, Inc. | -564.00 USD | 1341576.596% |
| Sonnet BioTherapeutics Holdings, Inc. | -11.66 Million USD | 164.85% |
| Immunovant, Inc. | -231 Thousand USD | 3375.294% |
| Vericel Corporation | 135.57 Million USD | 94.419% |
| Fortrea Holdings Inc. | 424 Million USD | 98.216% |
| KalVista Pharmaceuticals, Inc. | -86.16 Million USD | 108.781% |
| XBiotech Inc. | -1.74 Million USD | 533.826% |
| Agenus Inc. | 139.61 Million USD | 94.581% |
| Acasti Pharma Inc. | -11 Thousand USD | 68881.164% |
| Kiora Pharmaceuticals, Inc. | -4.02 Million USD | 287.878% |
| MiNK Therapeutics, Inc. | -204.61 Thousand USD | 3797.605% |
| Pasithea Therapeutics Corp. | -648.45 Thousand USD | 1266.764% |
| Theravance Biopharma, Inc. | 16.8 Million USD | 54.973% |
| Metagenomi, Inc. Common Stock | -49.64 Million USD | 115.239% |
| NeuroBo Pharmaceuticals, Inc. | - USD | -Infinity% |
| Gain Therapeutics, Inc. | -11.32 Million USD | 166.814% |
| Tempest Therapeutics, Inc. | -381 Thousand USD | 2085.808% |
| Sol-Gel Technologies Ltd. | -21.98 Million USD | 134.411% |
| Rhythm Pharmaceuticals, Inc. | 68.12 Million USD | 88.894% |
| United Therapeutics Corporation | 2.07 Billion USD | 99.634% |
| Creative Medical Technology Holdings, Inc. | 5400.00 USD | -140009.778% |
| BriaCell Therapeutics Corp. | -82.58 Thousand USD | 9261.605% |
| Lixte Biotechnology Holdings, Inc. | - USD | -Infinity% |
| Silo Pharma, Inc. | 66.26 Thousand USD | -11317.856% |
| Telomir Pharmaceuticals, Inc. Common Stock | -3.94 Million USD | 291.929% |
| Pharming Group N.V. | 220.1 Million USD | 96.563% |
| XOMA Corporation | 3.86 Million USD | -95.958% |
| Reviva Pharmaceuticals Holdings, Inc. | - USD | -Infinity% |
| Bionomics Limited | -434.44 Thousand USD | 1841.5% |
| Alpha Tau Medical Ltd. | -1.07 Million USD | 804.463% |
| Pyxis Oncology, Inc. | -2 Million USD | 478.296% |
| uniQure N.V. | 2.21 Million USD | -241.577% |
| Xilio Therapeutics, Inc. | -1.9 Million USD | 498.207% |
| Cassava Sciences, Inc. | -89.42 Million USD | 108.461% |
| 60 Degrees Pharmaceuticals, Inc. | -220.97 Thousand USD | 3523.853% |
| Windtree Therapeutics, Inc. | -82 Thousand USD | 9326.741% |
| Poseida Therapeutics, Inc. | -92.06 Million USD | 108.218% |
| Pluri Inc. | 322 Thousand USD | -2249.667% |
| Anebulo Pharmaceuticals, Inc. | - USD | -Infinity% |
| MeiraGTx Holdings plc | 287 Thousand USD | -2536.212% |
| Cidara Therapeutics, Inc. | 62.38 Million USD | 87.872% |
| ProMIS Neurosciences, Inc. | -10.44 Million USD | 172.436% |
| CalciMedica, Inc. | -58 Thousand USD | 13144.703% |
| Sana Biotechnology, Inc. | -30.86 Million USD | 124.513% |
| Amicus Therapeutics, Inc. | 362.03 Million USD | 97.91% |
| Salarius Pharmaceuticals, Inc. | -10.05 Thousand USD | 75375.376% |
| Alpha Tau Medical Ltd. | -1.07 Million USD | 804.463% |
| Adlai Nortye Ltd. American Depositary Shares | 2.77 Million USD | -172.589% |
| Nutriband Inc. | 862.1 Thousand USD | -777.611% |
| Protara Therapeutics, Inc. | -341 Thousand USD | 2318.747% |
| Compugen Ltd. | 31.45 Million USD | 75.947% |
| Roivant Sciences Ltd. | 109.23 Million USD | 93.074% |
| ProKidney Corp. | -3.16 Million USD | 338.748% |
| Protagenic Therapeutics, Inc. | -28.21 Thousand USD | 26912.418% |
| Elevai Labs, Inc. Common Stock | 1.13 Million USD | -566.848% |
| Tango Therapeutics, Inc. | -78.67 Million USD | 109.617% |
| Renovaro Biosciences Inc. | -121.85 Thousand USD | 6308.756% |
| Zevra Therapeutics, Inc. | 24.51 Million USD | 69.139% |
| Benitec Biopharma Inc. | 108 Thousand USD | -6905.489% |
| GeoVax Labs, Inc. | -20.72 Million USD | 136.514% |
| Biomea Fusion, Inc. | -4.2 Million USD | 280.098% |
| Cullinan Oncology, Inc. | -310 Thousand USD | 2540.622% |
| 4D Molecular Therapeutics, Inc. | -76.37 Million USD | 109.907% |
| Kiniksa Pharmaceuticals, Ltd. | 213.73 Million USD | 96.46% |
| Nuvectis Pharma, Inc. | -22.89 Million USD | 133.043% |
| Spyre Therapeutics, Inc. | -78 Thousand USD | 9799.908% |
| Ventyx Biosciences, Inc. | -941 Thousand USD | 904.031% |
| Imunon, Inc. | -720 Thousand USD | 1150.816% |
| BioAtla, Inc. | -103.73 Million USD | 107.294% |
| Allogene Therapeutics, Inc. | -242.81 Million USD | 103.116% |
| Larimar Therapeutics, Inc. | -311 Thousand USD | 2532.774% |
| Zura Bio Limited | - USD | -Infinity% |
| aTyr Pharma, Inc. | -2.38 Million USD | 416.831% |
| Madrigal Pharmaceuticals, Inc. | -527 Thousand USD | 1535.66% |
| Viridian Therapeutics, Inc. | -1 Million USD | 850.588% |
| Galecto, Inc. | -830 Thousand USD | 1011.558% |
| Tevogen Bio Holdings Inc. | - USD | -Infinity% |
| Halozyme Therapeutics, Inc. | 636.89 Million USD | 98.812% |
| Lexicon Pharmaceuticals, Inc. | 1.11 Million USD | -576.133% |
| PolyPid Ltd. | -1.82 Million USD | 515.254% |
| Aileron Therapeutics, Inc. | -119 Thousand USD | 6457.923% |
| Forte Biosciences, Inc. | -9000.00 USD | 84165.867% |
| Xencor, Inc. | -85.26 Million USD | 108.874% |
| Coeptis Therapeutics Holdings, Inc. | -1 Million USD | 855.659% |
| Lexaria Bioscience Corp. | 194.7 Thousand USD | -3785.782% |
| Instil Bio, Inc. | -4.75 Million USD | 259.082% |
| Cardio Diagnostics Holdings, Inc. | -94.55 Thousand USD | 8101.616% |
| OncoCyte Corporation | 413 Thousand USD | -1731.944% |
| Elevation Oncology, Inc. | -39 Thousand USD | 19499.815% |
| Purple Biotech Ltd. | -196 Thousand USD | 3960.167% |
| CollPlant Biotechnologies Ltd. | 8.96 Million USD | 15.634% |
| MacroGenics, Inc. | 50.52 Million USD | 85.026% |
| Verona Pharma plc | -679.62 Thousand USD | 1213.252% |
| Tharimmune, Inc. | - USD | -Infinity% |
| Apogee Therapeutics, Inc. | - USD | -Infinity% |
| enGene Holdings Inc. Warrants | -175 Thousand USD | 4423.387% |
| Aditxt, Inc. | -111.66 Thousand USD | 6875.862% |
| XTL Biopharmaceuticals Ltd. | - USD | -Infinity% |
| Savara Inc. | -44.26 Million USD | 117.094% |
| Curis, Inc. | 9.81 Million USD | 22.883% |
| Carmell Therapeutics Corporation | -124.78 Thousand USD | 6163.025% |
| Achieve Life Sciences, Inc. | -228 Thousand USD | 3418.389% |
| BeiGene, Ltd. | 2.07 Billion USD | 99.636% |
| Protagenic Therapeutics, Inc. | -28.21 Thousand USD | 26912.418% |
| Vincerx Pharma, Inc. | -915 Thousand USD | 926.877% |
| Plus Therapeutics, Inc. | -4.77 Million USD | 258.382% |
| Acrivon Therapeutics, Inc. Common Stock | -536 Thousand USD | 1511.554% |
| Rigel Pharmaceuticals, Inc. | 109.77 Million USD | 93.108% |
| Adicet Bio, Inc. | -6.09 Million USD | 224.072% |
| Estrella Immunopharma, Inc. | - USD | -Infinity% |
| Quantum-Si incorporated | 488 Thousand USD | -1450.395% |
| Acurx Pharmaceuticals, Inc. | - USD | -Infinity% |
| Generation Bio Co. | -73.91 Million USD | 110.237% |
| Black Diamond Therapeutics, Inc. | -437 Thousand USD | 1831.334% |
| Invivyd, Inc. | -2.02 Million USD | 473.073% |
| Relay Therapeutics, Inc. | -300.84 Million USD | 102.515% |
| Quoin Pharmaceuticals, Ltd. | -103.43 Thousand USD | 7414.457% |
| Moolec Science SA | -143.3 Thousand USD | 5379.598% |
| Clearside Biomedical, Inc. | 7.87 Million USD | 3.876% |
| Longboard Pharmaceuticals, Inc. | -5000.00 USD | 151418.56% |
| Relmada Therapeutics, Inc. | - USD | -Infinity% |
| ALX Oncology Holdings Inc. | -836 Thousand USD | 1005.015% |
| Vir Biotechnology, Inc. | 83.41 Million USD | 90.93% |
| Evaxion Biotech A/S | 73.11 Thousand USD | -10248.408% |
| Ocular Therapeutix, Inc. | 53.16 Million USD | 85.768% |
| Tyra Biosciences, Inc. | -353 Thousand USD | 2243.322% |
| Unity Biotechnology, Inc. | -19.69 Million USD | 138.408% |
| Connect Biopharma Holdings Limited | -988 Thousand USD | 865.782% |
| Clearmind Medicine Inc. | -56.34 Thousand USD | 13528.575% |
| Aadi Bioscience, Inc. | 21.54 Million USD | 64.883% |
| Catalyst Pharmaceuticals, Inc. | 313.67 Million USD | 97.588% |
| CERo Therapeutics Holdings, Inc. | - USD | -Infinity% |
| Viking Therapeutics, Inc. | -292 Thousand USD | 2691.071% |
| Keros Therapeutics, Inc. | -664 Thousand USD | 1239.447% |
| Crinetics Pharmaceuticals, Inc. | 4.01 Million USD | -88.535% |
| ImmunityBio, Inc. | -17.89 Million USD | 142.291% |
| Korro Bio, Inc. | -3.63 Million USD | 308.428% |
| Kineta, Inc. | 5.43 Million USD | -39.259% |
| BioVie Inc. | -229.37 Thousand USD | 3398.468% |
| Codexis, Inc. | 57.33 Million USD | 86.804% |
| Celularity Inc. | 6.75 Million USD | -12.005% |
| Virax Biolabs Group Limited | 50.59 Thousand USD | -14855.382% |
| Cibus, Inc. | 1.42 Million USD | -432.062% |
| Annexon, Inc. | -3.26 Million USD | 331.586% |
| Assembly Biosciences, Inc. | -41.73 Million USD | 118.128% |
| Eyenovia, Inc. | - USD | -Infinity% |
| Puma Biotechnology, Inc. | 172.95 Million USD | 95.625% |
| NeurAxis, Inc. | 2.15 Million USD | -250.81% |
| Regulus Therapeutics Inc. | -21.15 Million USD | 135.769% |
| Compass Therapeutics, Inc. | -1.89 Million USD | 500.314% |
| TFF Pharmaceuticals, Inc. | 231.39 Thousand USD | -3169.759% |
| Notable Labs, Ltd. | 113 Thousand USD | -6595.512% |
| IN8bio, Inc. | -2.5 Million USD | 402.516% |
| DiaMedica Therapeutics Inc. | -30 Thousand USD | 25319.76% |
| Vera Therapeutics, Inc. | 1.86 Million USD | -306.333% |
| Lumos Pharma, Inc. | 2 Million USD | -276.977% |
| Liquidia Corporation | 14.6 Million USD | 48.179% |
| Mustang Bio, Inc. | -2.22 Million USD | 440.042% |
| Quantum-Si incorporated | 488 Thousand USD | -1450.395% |
| Arbutus Biopharma Corporation | -55.55 Million USD | 113.618% |
| enGene Holdings Inc. Common Stock | -175 Thousand USD | 4423.387% |
| ARS Pharmaceuticals, Inc. | -20.03 Million USD | 137.762% |
| 180 Life Sciences Corp. | -105.67 Thousand USD | 7259.62% |
| Vaxcyte, Inc. | -75 Million USD | 110.088% |
| Xenon Pharmaceuticals Inc. | -167.51 Million USD | 104.517% |
| Estrella Immunopharma, Inc. | - USD | -Infinity% |
| NKGen Biotech, Inc. Warrants | -1.2 Million USD | 728.922% |
| Opiant Pharmaceuticals, Inc. | 31.65 Million USD | 76.102% |
| CERo Therapeutics Holdings, Inc. | - USD | -Infinity% |
| Soleno Therapeutics, Inc. | -1.95 Million USD | 486.411% |
| PepGen Inc. | -1.18 Million USD | 739.014% |
| Moleculin Biotech, Inc. | -127 Thousand USD | 6057.424% |
| Solid Biosciences Inc. | -76.56 Million USD | 109.882% |
| Palisade Bio, Inc. | 246 Thousand USD | -2975.58% |
| Nutriband Inc. | 862.1 Thousand USD | -777.611% |
| Conduit Pharmaceuticals Inc. | - USD | -Infinity% |
| Immuneering Corporation | -764.13 Thousand USD | 1090.126% |
| Belite Bio, Inc | -399 Thousand USD | 1996.223% |
| CG Oncology, Inc. Common stock | -45.54 Million USD | 116.611% |
| GeoVax Labs, Inc. | -20.72 Million USD | 136.514% |
| Tourmaline Bio, Inc. | -33 Thousand USD | 23027.055% |
| Altimmune, Inc. | -65.37 Million USD | 111.573% |
| Peak Bio, Inc. | 367.76 Thousand USD | -1957.25% |
| SeaStar Medical Holding Corporation | - USD | -Infinity% |
| FibroBiologics, Inc. Common Stock | -437 Thousand USD | 1831.334% |
| Neurogene Inc. | -3.26 Million USD | 331.941% |
| Mirum Pharmaceuticals, Inc. | 139.33 Million USD | 94.57% |
| Kintara Therapeutics, Inc. | -55 Thousand USD | 13856.233% |
| CARGO Therapeutics, Inc. Common Stock | -3.69 Million USD | 304.928% |
| Sesen Bio, Inc. | 40 Million USD | 81.085% |
| argenx SE | 1.1 Billion USD | 99.317% |
| NKGen Biotech, Inc. Common Stock | -1.2 Million USD | 728.922% |
| Dianthus Therapeutics, Inc. | 2.47 Million USD | -206.189% |
| Immunome, Inc. | -8.9 Million USD | 184.944% |
| Enveric Biosciences, Inc. | -408.03 Thousand USD | 1954.258% |
| Design Therapeutics, Inc. | -537 Thousand USD | 1508.925% |
| Seelos Therapeutics, Inc. | 2.14 Million USD | -252.56% |
| Enliven Therapeutics, Inc. | -297 Thousand USD | 2647.451% |
| Iovance Biotherapeutics, Inc. | -9.56 Million USD | 179.092% |
| Taysha Gene Therapies, Inc. | 14.08 Million USD | 46.265% |
| Inovio Pharmaceuticals, Inc. | -2.67 Million USD | 383.206% |
| Athira Pharma, Inc. | -969 Thousand USD | 880.798% |
| XOMA Corporation | 3.86 Million USD | -95.958% |
| Merus N.V. | -83.46 Million USD | 109.065% |
| Quince Therapeutics, Inc. | -322 Thousand USD | 2449.667% |
| Rezolute, Inc. | -36 Thousand USD | 21116.467% |
| Clene Inc. | 533 Thousand USD | -1319.499% |
| Indaptus Therapeutics, Inc. | -1284.00 USD | 589346.729% |
| BeyondSpring Inc. | 1.75 Million USD | -332.092% |
| Synlogic, Inc. | -1.92 Million USD | 493.24% |
| Allarity Therapeutics, Inc. | -37 Thousand USD | 20548.454% |
| Phio Pharmaceuticals Corp. | -6.33 Million USD | 219.487% |
| Peak Bio, Inc. | 367.76 Thousand USD | -1957.25% |
| Werewolf Therapeutics, Inc. | -18.96 Million USD | 139.898% |
| Krystal Biotech, Inc. | 47.6 Million USD | 84.107% |
| Karyopharm Therapeutics Inc. | 141.09 Million USD | 94.638% |
| SpringWorks Therapeutics, Inc. | 5.02 Million USD | -50.566% |
| Lipella Pharmaceuticals Inc. | -2.58 Million USD | 392.209% |
| MannKind Corporation | 136.19 Million USD | 94.445% |
| Ikena Oncology, Inc. | -50.49 Million USD | 114.984% |
| Cyclerion Therapeutics, Inc. | - USD | -Infinity% |
| Gyre Therapeutics, Inc. | 108.81 Million USD | 93.047% |
| Gossamer Bio, Inc. | -4.38 Million USD | 272.541% |
| CohBar, Inc. | - USD | -Infinity% |
| Cognition Therapeutics, Inc. | -252 Thousand USD | 3102.352% |
| NRx Pharmaceuticals, Inc. | -5000.00 USD | 151418.56% |
| Legend Biotech Corporation | 140.92 Million USD | 94.631% |
| Mural Oncology plc | -2.56 Million USD | 394.738% |
| Disc Medicine, Inc. | -100 Thousand USD | 7665.928% |
| Champions Oncology, Inc. | 20.75 Million USD | 63.545% |
| REGENXBIO Inc. | 53.02 Million USD | 85.732% |
| Ensysce Biosciences, Inc. | -5.35 Million USD | 241.236% |
| Anavex Life Sciences Corp. | - USD | -Infinity% |
| Cellectar Biosciences, Inc. | -192.37 Thousand USD | 4032.906% |
| Edgewise Therapeutics, Inc. | -1.73 Million USD | 536.832% |
| Vaxart, Inc. | -60.76 Million USD | 112.452% |
| PharmaCyte Biotech, Inc. | - USD | -Infinity% |
| Aldeyra Therapeutics, Inc. | -262.78 Thousand USD | 2979.187% |
| Cellectis S.A. | 18 Thousand USD | -41932.933% |
| Longeveron Inc. | 221 Thousand USD | -3323.497% |
| Repare Therapeutics Inc. | -80.07 Million USD | 109.449% |
| Sarepta Therapeutics, Inc. | 1.09 Billion USD | 99.308% |
| Inozyme Pharma, Inc. | -1.29 Million USD | 684.693% |
| Revolution Medicines, Inc. | -399.66 Million USD | 101.893% |
| Nymox Pharmaceutical Corporation | - USD | -Infinity% |
| Third Harmonic Bio, Inc. | -35 Thousand USD | 21716.937% |
| ArriVent BioPharma, Inc. Common Stock | - USD | -Infinity% |
| AN2 Therapeutics, Inc. | - USD | -Infinity% |
| Anixa Biosciences, Inc. | 49 Thousand USD | -15340.669% |
| Vertex Pharmaceuticals Incorporated | 8.6 Billion USD | 99.912% |
| Denali Therapeutics Inc. | -93.34 Million USD | 108.105% |
| Revelation Biosciences, Inc. | -25.04 Thousand USD | 30304.511% |
| Corvus Pharmaceuticals, Inc. | -151 Thousand USD | 5110.548% |
| Cingulate Inc. | -582.91 Thousand USD | 1397.94% |
| Passage Bio, Inc. | -3.72 Million USD | 303.331% |
| Context Therapeutics Inc. | -12.04 Thousand USD | 62919.063% |
| Exicure, Inc. | -1.42 Million USD | 631.689% |
| Day One Biopharmaceuticals, Inc. | -383 Thousand USD | 2075.438% |
| Oramed Pharmaceuticals Inc. | 2.7 Million USD | -179.909% |
| Scinai Immunotherapeutics Ltd. | -512.67 Thousand USD | 1575.775% |
| Nuvalent, Inc. | - USD | -Infinity% |
| ABVC BioPharma, Inc. | -149.6 Thousand USD | 5157.202% |
| Carisma Therapeutics, Inc. | -59.2 Million USD | 112.779% |
| Unicycive Therapeutics, Inc. | 391 Thousand USD | -1835.02% |
| OmniAb, Inc. | 14.66 Million USD | 48.415% |
| Anew Medical, Inc. | - USD | -Infinity% |
| Fennec Pharmaceuticals Inc. | 19.99 Million USD | 62.157% |
| Lipocine Inc. | -2.85 Million USD | 365.395% |
| Lexeo Therapeutics, Inc. Common Stock | -1.84 Million USD | 510.522% |
| Nautilus Biotechnology, Inc. | -5.7 Million USD | 232.619% |
| SAB Biotherapeutics, Inc. | -1.5 Million USD | 602.289% |
| G1 Therapeutics, Inc. | 75.31 Million USD | 89.954% |
| Bellerophon Therapeutics, Inc. | -65 Thousand USD | 11739.889% |
| Sage Therapeutics, Inc. | 84.29 Million USD | 91.025% |
| Ocugen, Inc. | -33.53 Million USD | 122.56% |
| Mind Medicine (MindMed) Inc. | -3.16 Million USD | 339.277% |
| Q32 Bio Inc. | 578 Thousand USD | -1208.984% |
| Brainstorm Cell Therapeutics Inc. | -265 Thousand USD | 2955.067% |
| Alumis Inc. Common Stock | -1.28 Million USD | 689.247% |
| Equillium, Inc. | 35.95 Million USD | 78.959% |
| Kyverna Therapeutics, Inc. | -1.7 Million USD | 543.23% |
| Coya Therapeutics, Inc. | 500.67 Thousand USD | -1411.133% |
| CNS Pharmaceuticals, Inc. | -4134.00 USD | 183117.126% |
| Dominari Holdings Inc. | 2.03 Million USD | -271.061% |
| Edesa Biotech, Inc. | -183.47 Thousand USD | 4223.773% |
| vTv Therapeutics Inc. | -13.59 Million USD | 155.652% |
| Bio-Techne Corporation | 773.07 Million USD | 99.021% |
| Agios Pharmaceuticals, Inc. | 17.31 Million USD | 56.314% |
| Harmony Biosciences Holdings, Inc. | 460.78 Million USD | 98.358% |
| Prelude Therapeutics Incorporated | -1.16 Million USD | 747.214% |
| Candel Therapeutics, Inc. | -23.98 Million USD | 131.551% |
| iTeos Therapeutics, Inc. | 11.69 Million USD | 35.317% |
| Nkarta, Inc. | -5.86 Million USD | 228.913% |
| BioCardia, Inc. | -7.24 Million USD | 204.372% |
| Iterum Therapeutics plc | -1.75 Million USD | 532.339% |